Related Experiment Video
Updated: May 12, 2026

Two-vessel Occlusion Mouse Model of Cerebral Ischemia-reperfusion
Published on: March 1, 2019
Cerebral ischemia-reperfusion injury: mechanisms and promising therapies
Mingming Yang1, Boya Liu2, Bingqian Chen3
1Department of Pediatrics, Binhai County People's Hospital, Yancheng, Jiangsu, China.
Abstract:
Cerebral ischemia-reperfusion injury (Cerebral I/R injury) is a critical pathological process following ischemic stroke, closely associated with multiple mechanisms including oxidative stress, neuroinflammation, and neuronal apoptosis. It also involves the alteration and regulation of numerous key genes and non-coding RNAs. Due to its complex regulatory mechanisms, there are currently no Food and Drug Administration (FDA)-approved drugs specifically targeting Cerebral I/R injury. Developing effective therapeutic strategies for Cerebral I/R injury remains a significant challenge in medical research. This review summarizes current treatment approaches for Cerebral I/R injury, which include traditional drugs, antioxidants, neuroprotective agents, exosomes, noncoding RNA therapeutics and combined intervention therapy. Pharmacotherapies exert positive effects on Cerebral I/R injury through antioxidative, anti-inflammatory, and neuroprotective mechanisms. Exosomes and noncoding RNA therapeutics can mitigate brain cell damage and promote neural function recovery by regulating the expression of downstream key genes via miRNAs, demonstrating potential as novel therapeutic options. Emerging evidence indicates that combined therapeutic strategies incorporating nanoparticle-mediated targeting demonstrate efficacy in treating cerebral I/R injury. By exploring the mechanisms of action and clinical application prospects of these different treatment strategies, this review aims to provide new insights and methods for the clinical management of Cerebral I/R injury.
Insights
Cerebral ischemia-reperfusion (I/R) injury treatments are complex, lacking FDA approval. This review explores current and novel therapies like pharmacotherapies, exosomes, and noncoding RNAs for managing brain injury after stroke.
Area of Science:
- Neuroscience
- Biomedical Engineering
- Pharmacology
Background:
- Cerebral ischemia-reperfusion (I/R) injury is a major cause of disability after stroke.
- It involves oxidative stress, neuroinflammation, and apoptosis, with complex genetic regulation.
- No FDA-approved drugs specifically target Cerebral I/R injury, highlighting a critical unmet medical need.
Purpose of the Study:
- To review current and emerging therapeutic strategies for Cerebral I/R injury.
- To explore the mechanisms of action for various treatments.
- To provide insights into clinical application prospects for Cerebral I/R injury management.
Main Methods:
- Literature review of existing research on Cerebral I/R injury treatments.
- Analysis of pharmacotherapies, including traditional drugs, antioxidants, and neuroprotective agents.
- Evaluation of novel approaches such as exosomes, noncoding RNA therapeutics, and combined interventions.
Main Results:
- Pharmacotherapies offer benefits via antioxidative, anti-inflammatory, and neuroprotective effects.
- Exosomes and noncoding RNAs show promise in mitigating brain damage and promoting recovery by regulating gene expression.
- Combined strategies, particularly those using nanoparticle-mediated targeting, demonstrate significant therapeutic efficacy.
Conclusions:
- Current treatments for Cerebral I/R injury are diverse, including pharmacotherapies and advanced biological agents.
- Exosomes and noncoding RNAs represent promising novel therapeutic avenues.
- Combined and targeted therapies hold significant potential for improving clinical outcomes in Cerebral I/R injury.
Related Concept Videos
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology

